![Samir Khleif](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Samir Khleif
Corporate Officer/Principal bei INTELLIGENT MEDICINE ACQUISITION CORP.
Vermögen: 15 $ am 31.05.2024
Profil
Samir N.
Khleif is the founder of Georgiamune, Inc. He currently holds multiple positions including Chief Executive Officer at King Hussein Cancer Center, Director at Augusta University, Director at Georgia Cancer Center, Venture Advisor at Israel Biotech Fund, and Advisor at Intelligent Medicine Acquisition Corp.
Previously, he served as an Independent Director at Advaxis, Inc., Director at Ayala Pharmaceuticals, Inc., and Chief-Cancer Vaccine Section at National Cancer Institute.
Khleif received his undergraduate degree from Augusta University and his graduate degree from the University of Jordan Medical School in 1986.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
12.12.2022 | 59 ( 0,00% ) | 15 $ | 31.05.2024 |
Aktive Positionen von Samir Khleif
Unternehmen | Position | Beginn |
---|---|---|
INTELLIGENT MEDICINE ACQUISITION CORP. | Corporate Officer/Principal | - |
Augusta University | Direktor/Vorstandsmitglied | - |
Georgia Cancer Center | Direktor/Vorstandsmitglied | - |
Georgiamune, Inc.
![]() Georgiamune, Inc. BiotechnologyHealth Technology Georgiamune, Inc. is a clinical stage biotechnology company that focuses on reprogramming immune signaling pathways to redirect the immune system to fight diseases. The company is based in Silver Spring, MD. The company has designed unique approaches to re-establish immune balance, and its scientific discoveries have led to pioneering immunotherapies targeting high unmet needs. Georgiamune's lead program, Gim-122, is a first-in-class, dual-functioning monoclonal antibody designed to overcome immune therapy resistance in cancer patients. In addition to its lead program, the company is advancing a pipeline of first-in-class therapies for cancer and autoimmune diseases. The company was founded by Samir N. Khleif, a world-renowned medical oncologist and researcher in the field of immunology and cancer, based on discoveries in his lab on novel mechanisms to modulate immune response. Samir N. Khleif has been the CEO since incorporation. | Vorstandsvorsitzender | - |
King Hussein Cancer Center | Vorstandsvorsitzender | - |
Israel Biotech Fund
![]() Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Berater | - |
Ehemalige bekannte Positionen von Samir Khleif
Unternehmen | Position | Ende |
---|---|---|
AYALA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 19.10.2023 |
National Cancer Institute
![]() National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
AYALA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Samir Khleif
Augusta University | Undergraduate Degree |
University of Jordan Medical School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AYALA PHARMACEUTICALS, INC. | Commercial Services |
Private Unternehmen | 7 |
---|---|
Advaxis, Inc.
![]() Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
Georgia Cancer Center | |
National Cancer Institute
![]() National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
Intelligent Medicine Acquisition Corp.
![]() Intelligent Medicine Acquisition Corp. Electrical ProductsProducer Manufacturing Intelligent Medicine Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Bethesda, MD. | Producer Manufacturing |
Georgiamune, Inc.
![]() Georgiamune, Inc. BiotechnologyHealth Technology Georgiamune, Inc. is a clinical stage biotechnology company that focuses on reprogramming immune signaling pathways to redirect the immune system to fight diseases. The company is based in Silver Spring, MD. The company has designed unique approaches to re-establish immune balance, and its scientific discoveries have led to pioneering immunotherapies targeting high unmet needs. Georgiamune's lead program, Gim-122, is a first-in-class, dual-functioning monoclonal antibody designed to overcome immune therapy resistance in cancer patients. In addition to its lead program, the company is advancing a pipeline of first-in-class therapies for cancer and autoimmune diseases. The company was founded by Samir N. Khleif, a world-renowned medical oncologist and researcher in the field of immunology and cancer, based on discoveries in his lab on novel mechanisms to modulate immune response. Samir N. Khleif has been the CEO since incorporation. | Health Technology |
King Hussein Cancer Center | |
Israel Biotech Fund
![]() Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |